Navigation Links
The current state of lung cancer treatment
Date:12/11/2012

l chemotherapies, and with much reduced side effects.

But with this great promise of picking off cancer varieties one-by-one according to their oncogenes comes the challenge of testing drugs that are effective in perhaps only one of every 100 lung cancer patients. The challenge is twofold: enrolling enough patients on a clinical trial to make the results meaningful, and securing funding for a trial in which the drug will only be marketable to a small slice of the lung cancer population.

"How do you get drug approvals for what we'd normally call orphan diseases?" Bunn asks.

Then, Bunn points to the major challenge of staying ahead of lung cancer as it mutates in response to these targeted first-line drugs. "Targeted therapies don't cure patients yet," Bunn says. Instead, lung cancer eventually mutates around the drug's effectiveness. "And so we have to discover the most rational combinations and see if these combinations allow complete response," Bunn says.

In addition to therapies targeting oncogenes, Bunn describes completely new approaches to treating the disease, including Phase III clinical trials of lung cancer vaccines that aid the body's immune response against the cancer, and the search for ways to promote the function of tumor-suppressor genes that are commonly turned off in cancers.

What is clear is that after many years of chemotherapy and radiation, we're in the midst of an explosion in novel lung cancer treatment options.

"In the coming few years it is likely that we will identify additional 'actionable' molecular drivers treated with specific oral inhibitors," Bunn says. "We're already up to 30 or 40 percent of lung cancers that are susceptible to targeted therapies. I don't know if we'll reach 100 percent but the number is certain to grow."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases
2. Triple negative breast cancer symposium highlights current advances
3. Why current strategies for fighting obesity are not working
4. Current and former smokers at risk for recurrent hepatitis post-liver transplantation
5. DMP module on heart failure: Current guidelines indicate some need for revision
6. Study suggests new way to prevent recurrent ear infections
7. Daily Aspirin May Help Those at Risk for Recurrent Blood Clots
8. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
9. Benefit of PET or PET/CT in recurrent bowel cancer is not proven
10. Study reveals how cancer drug causes diabetic-like state
11. New drug prevents spread of human prostate cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... rats bearing human breast tumors, exposure to dim light ... cancer drug tamoxifen, according to data published in ... for Cancer Research. The negative effects of dim light ... a melatonin supplement during the night. , "Resistance to ... receptor-positive breast cancer," said Steven M. Hill, PhD, professor ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap Manchester ... Authority Field on July 26th. For the past four years, the ... the best club teams from around the world to North America ... weeks after its completion, fans – new and old alike – ... in the world compete. Some of these players were already members ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. District Court, ... order for plaintiff medical information covered by the ... to the July 16th Order, U.S. District Judge ... for Fresenius Medical Care the right to receive ...
(Date:7/24/2014)... Association Executives (ASAE) announced its 2014 Power of A ... Society of Anesthesiologists (ASA). , The ASA Global ... Gold Award, one of the top honors from ASAE. ... the world through education on the global anesthesia crisis ... , ASA was also honored with a Power of ...
(Date:7/24/2014)... July 24, 2014 Pools and beaches are ... water can be dangerous, especially for small children, so ... safety. , According to the Centers for Disease Control and ... most at risk for water-related injuries and deaths. It’s important ... around water, so Amica is offering the following tips from ...
Breaking Medicine News(10 mins):Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... book, written by Dr. Vardit Rispler-Chaim of the Department ... Haifa, analyzes attitudes to people with various ... Middle Ages and the modern era. , In the ... and often within broad topics such as religious duties, ...
... focus on issues most critical to health care ... selected as new survey vendor, WASHINGTON, Dec. 12 ... non-profit organization of employer-based,health coalitions, released its 2008 eValue8(TM) ... health care purchasers to compare,the quality and efficiency of ...
... Dec. 12 INVEGA(TM) (paliperidone),Extended-Release Tablets showed ... open-label extension (OLE) study, according to a ... improved or,were stable, on average, over this ... to evaluate the long-term safety of INVEGA, ...
... had harder time fighting gum disease , , WEDNESDAY, ... harder to fight infections, and a weakened immune response ... Boston University researchers. , In experiments with mice infected ... had less ability to battle gum infection than their ...
... and Providers, AUSTIN, Texas, Dec. 12 ... report, U.S. taxpayers are annually defrauded of,about $60 ... health,care providers. A new system developed by S3 ... significant impact on reducing Medicare,and Medicaid fraud with ...
... by the,positive results of the 2007 Monitoring the Future ... in the right direction,with significant declines in overall teen ... for all measured age groups marking steady long-term,reductions in ... MTF, now in its 33rd year, is an ...
Cached Medicine News:Health News:National Business Coalition on Health Releases 2008 eValue8(TM) RFI 2Health News:National Business Coalition on Health Releases 2008 eValue8(TM) RFI 3Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 2Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 3Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 4Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 5Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 6Health News:Obesity Weakens Immune Response 2Health News:Technology can Dramatically Reduce Billions of Dollars in Medicaid, Medicare Fraud 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 4
(Date:7/24/2014)... 2014  IRIDEX Corporation (NASDAQ: IRIX ) ... 2014 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, July 31, 2014 to ... developments. Interested parties may access the live ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - Panacos,Pharmaceuticals, ... the next generation of antiviral,therapeutic products, today ... that HIV resistant to Protease Inhibitors (PI) ... resistance to the HIV,maturation inhibitor bevirimat in ...
... Taxotere(R) and on three investigational,agents (VEGF Trap, S-1 ... ASCO meeting, BRIDGEWATER, N.J., May 29, 2007 /PRNewswire-FirstCall/ ... abstracts,indicative of its oncology commitment have been accepted ... of Clinical Oncology,(ASCO) in Chicago, Illinois (June 1-5, ...
Cached Medicine Technology:Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat 2Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12
Indications For Usage: , Airway management during surgical procedures. , Long-term ventilatory management. ...
Indications For Usage: , Nasal surgery. , Ophthalmic surgery. , Facial surgery. , T&A surgery. ...
Indications For Usage: ,Airway management during pediatric surgical procedures and intensive care....
The Cuffed Endoflex endotracheal tube had a murphy eye, high volume, low pressure cuff., ,Endoflex endotracheal tubes are individual packaged in sterilized pouches, 10 units per box, 10 boxes pe...
Medicine Products: